Skip to main content
SpringerLink
Log in

CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients

Data from the DEBATE Study

  • Original Research Article
  • Published:
American Journal of Pharmacogenomics

Abstract

Objective: The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension.

Method: We studied 373 elderly (age ≥75 years) Finnish (Caucasian) patients from the ongoing DEBATE (Drugs and Evidence Based Medicine in the Elderly) trial. The patients were classified into those with a history of hypertension (n = 229) and those without a history of hypertension (n = 144) on the basis of a detailed questionnaire on each patient’s medical history and an interview. The patients were genotyped for the CYP3A5 6986A/G single nucleotide polymorphism (SNP) [CYP3A5*1/*3 alleles].

Results: The proportion of individuals with the CYP3A5*1/*3 genotype, i.e. CYP3A5 expressors, was significantly higher among patients with a diagnosis of hypertension than among patients without (18.3% vs 9.0%, p = 0.016). The corresponding odds ratio was 2.26 (95% CI 1.17, 4.38). The allele and genotype frequencies for the two control SNPs, ABCB1 (MDR1) 3435C/T and SLCO1B1 521T/C, did not differ between the two groups.

Conclusion: This work lends support to the theory that the polymorphic CYP3A5 enzyme may be involved in regulation of blood pressure. The possible role of CYP3A5 as a genetic contributor to hypertension susceptibility warrants further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297–300

    PubMed  CAS  Google Scholar 

  2. Langaee TY, Givens RC, Sloan A, et al. Association of CYP3A5*3, *6, and *7 polymorphisms with hypertension [abstract]. Clin Pharmacol Ther 2004; 75: 13

    Article  Google Scholar 

  3. Ho H, Pinto A, Hall SD, et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005; 45: 294–8

    Article  PubMed  CAS  Google Scholar 

  4. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773–9

    Article  PubMed  CAS  Google Scholar 

  5. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–91

    Article  PubMed  CAS  Google Scholar 

  6. Schuetz EG, Schuetz JD, Grogan WM, et al. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992; 294: 206–14

    Article  PubMed  CAS  Google Scholar 

  7. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52–9

    PubMed  CAS  Google Scholar 

  8. Watlington CO, Kramer LB, Schuetz EG, et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992; 262: F927–31

    PubMed  CAS  Google Scholar 

  9. Ghosh S, Grogan WM, Basu A, et al. Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. Biochim Biophys Acta 1993; 1182: 152–6

    Article  PubMed  CAS  Google Scholar 

  10. Ghosh SS, Basu AK, Ghosh S, et al. Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem Pharmacol 1995; 50: 49–54

    Article  PubMed  CAS  Google Scholar 

  11. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207–13

    PubMed  CAS  Google Scholar 

  12. Duncan RL, Grogan WM, Kramer LB, et al. Corticosterone’s metabolite is an agonist for Na+ transport stimulation in A6 cells. Am J Physiol 1988; 255: F736–48

    PubMed  CAS  Google Scholar 

  13. Strandberg TE, Pitkälä K, Berglind S, et al. Multifactorial cardiovascular disease prevention in patients aged 75 years and older: a randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Am Heart J 2001; 142: 945–51

    Article  PubMed  CAS  Google Scholar 

  14. Strandberg TE, Pitkälä K, Berglind S, et al. Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Eur Heart J 2003; 24: 1216–22

    Article  PubMed  Google Scholar 

  15. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43: 285–307

    Article  PubMed  CAS  Google Scholar 

  16. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669–75

    Article  PubMed  CAS  Google Scholar 

  17. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004; 14: 429–40

    Article  PubMed  CAS  Google Scholar 

  18. Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 2002; 12: 529–34

    Article  PubMed  CAS  Google Scholar 

  19. King BP, Leathart JB, Mutch E, et al. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003; 55: 625–9

    Article  PubMed  CAS  Google Scholar 

  20. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 (OATP1B1) is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. In press

  21. Amudha K, Wong LP, Choy AM, et al. Ethnicity and drug therapy for hypertension. Curr Pharm Des 2003; 9: 1691–701

    Article  PubMed  CAS  Google Scholar 

  22. Stein CM, Lang CC, Xie HG, et al. Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of inter-individual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics 2001; 11: 95–110

    Article  PubMed  CAS  Google Scholar 

  23. Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4: 151–60

    Article  PubMed  CAS  Google Scholar 

  24. Watson Jr B. Genetics of the kidney and hypertension. Curr Hypertens Rep 2003; 5: 273–6

    Article  PubMed  Google Scholar 

  25. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82: 131–85

    PubMed  CAS  Google Scholar 

  26. Zhao X, Imig JD. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003; 4: 73–84

    Article  PubMed  CAS  Google Scholar 

  27. Rifkind AB, Lee C, Chang TK, et al. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995; 320: 380–9

    Article  PubMed  CAS  Google Scholar 

  28. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27: 481–90

    Article  PubMed  CAS  Google Scholar 

  29. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–72

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Robert-Bosch Foundation (Stuttgart, Germany), the Academy of Finland (grant no. 48613), and the Helsinki University Central Hospital (Helsinki, Finland). Dr Niemi was supported by a fellowship from the Alexander von Humboldt Foundation (Bonn, Germany).

The authors have identified no conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, Stuttgart, D-70376, Germany

    Kari T. Kivistö, Mikko Niemi, Elke Schaeffeler, Martin F. Fromm, Matthias Schwab & Michel Eichelbaum

  2. Department of Clinical Pharmacology, Helsinki University Central Hospital, Helsinki, Finland

    Mikko Niemi

  3. Department of Medicine, Geriatric Clinic, University of Helsinki, Helsinki, Finland

    Kaisu Pitkälä, Reijo Tilvis & Timo Strandberg

  4. Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany

    Martin F. Fromm

  5. Department of Physiology, University of Tübingen, Tübingen, Germany

    Florian Lang

Authors
  1. Kari T. Kivistö
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mikko Niemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elke Schaeffeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kaisu Pitkälä
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reijo Tilvis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin F. Fromm
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matthias Schwab
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Florian Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michel Eichelbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Timo Strandberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kari T. Kivistö.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kivistö, K.T., Niemi, M., Schaeffeler, E. et al. CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients. Am J Pharmacogenomics 5, 191–195 (2005). https://doi.org/10.2165/00129785-200505030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129785-200505030-00005

Keywords

Search

Navigation